Seaport Global Securities reaffirmed their buy rating on shares of Evoke Pharma, Inc. (NASDAQ:EVOK) in a research note published on Friday, October 6th, Marketbeat reports. Seaport Global Securities currently has a $10.00 target price on the specialty pharmaceutical company’s stock.
A number of other analysts have also recently commented on EVOK. Zacks Investment Research cut shares of Evoke Pharma from a hold rating to a sell rating in a research note on Thursday, August 17th. HC Wainwright restated a buy rating and set a $9.00 price target on shares of Evoke Pharma in a research note on Tuesday, August 15th. Finally, ValuEngine cut shares of Evoke Pharma from a hold rating to a sell rating in a research note on Friday, July 28th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. Evoke Pharma currently has a consensus rating of Buy and a consensus target price of $8.86.
Shares of Evoke Pharma (NASDAQ:EVOK) opened at 3.40 on Friday. Evoke Pharma has a 12 month low of $1.35 and a 12 month high of $4.55. The firm’s 50-day moving average is $3.30 and its 200 day moving average is $2.76. The firm’s market capitalization is $52.32 million.
Evoke Pharma (NASDAQ:EVOK) last released its earnings results on Monday, August 14th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.15). During the same quarter in the previous year, the company earned ($0.41) EPS. On average, equities research analysts anticipate that Evoke Pharma will post ($0.87) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This article was posted by BBNS and is owned by of BBNS. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://baseballnewssource.com/markets/seaport-global-securities-begins-coverage-on-evoke-pharma-inc-evok/1703178.html.
An institutional investor recently raised its position in Evoke Pharma stock. State Treasurer State of Michigan boosted its position in Evoke Pharma, Inc. (NASDAQ:EVOK) by 37.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 400,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 108,034 shares during the quarter. State Treasurer State of Michigan owned about 2.60% of Evoke Pharma worth $1,024,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 12.88% of the stock is owned by institutional investors.
Evoke Pharma Company Profile
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with our FREE daily email newsletter.